Advancing Menopause Care and Mid-Life Women’s Health Act

On June 2, 2026, Representative Yvette Clarke (D-NY-9) introduced HR9090, the Advancing Menopause Care and Mid-Life Women's Health Act, in the House. The bill was referred to the Committee on Energy and Commerce, marking its first legislative step. The bill text outlines provisions for NIH-coordinated research on menopause and mid-life women's health, public health awareness campaigns, training programs for healthcare providers, and the establishment of centers of excellence. However, the bill does not include any specific dollar amounts for authorized programs—it is an authorization bill that sets policy direction without appropriating funds. Actual spending would require a separate appropriations bill, which has not been introduced. The legislative process is at its earliest stage: introduction and committee referral. No hearings, markups, or votes have occurred. The sponsor is a junior member of the minority party, which reduces the likelihood of rapid advancement. Given the absence of a funding mechanism and the early procedural status, there is no identifiable near-term revenue impact on any publicly traded company. The bill's provisions are too broad and unfunded to create a direct causal chain to specific corporate revenues. No real market data was provided for healthcare tickers, and the bill does not name any company or product. The competitive landscape for women's health therapeutics (e.g., $LLY, $JNJ, $PFE) remains unchanged by this procedural action. The next steps include potential committee hearings, a markup, and a floor vote in the House, followed by Senate consideration—a process that typically takes months to years, if it advances at all.